Pineal gland astrocytoma

Summary

Pineal gland astrocytoma (MONDO:0003171) is a disease and 1 clinical trial. Top therapeutic interventions include aldesleukin. A subtype of diencephalic astrocytomas — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pineal gland astrocytoma
Mondo ID	MONDO:0003171
DOID	DOID:4858
NCIT	C8274
UMLS	C0280795
MedGen	83711
GARD	0023395
Anatomy (UBERON)	UBERON:0001905
Is cancer (heuristic)	no

Also known as: astrocytoma (excluding glioblastoma) of pineal body · astrocytoma of pineal gland · astrocytoma of the pineal gland · pineal astrocytic tumour · pineal astrocytoma · pineal body astrocytoma · pineal body astrocytoma (excluding glioblastoma)

Disease family

This is a subtype of diencephalic astrocytomas. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › brain cancer › supratentorial cancer › diencephalic cancer › diencephalic astrocytomas › pineal gland astrocytoma

Related subtypes (2): pituicytoma, optic tract astrocytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01082926	PHASE1	COMPLETED	Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALDESLEUKIN	4	1